Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Prophylactic LA-rFVIIa in Haemophilia with Inhibitors
NCT00951405Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Sep 2009
- Primary completion
- Mar 2011
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 11
01
Overview
Phase 2, randomised, double-blind trial of eptacog alfa pegol (activated) in hemophilia A and hemophilia B (HB) (3 arms), sponsored by Novo Nordisk. Primary endpoints: Thrombogenicity and Immunogenicity: Neutralising Antibody Development. Started Sep 2009; status: completed.
02
Drugs
eptacog alfa pegol (activated)
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on NCT00951405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00951405.